Hosts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Emily Sims, MD, to discuss the latest clinical evidence on teplizumab and other emerging treatments that can delay the onset of type 1 diabetes.
Applying the Latest Evidence to Delay the Onset of Type 1 Diabetes
Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes
Expert healthcare practitioners discuss the potential of CGM and other technology to identify signs of type 1 diabetes.
Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.
Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5